Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols



A.D.A.M. Medical Encyclopedia. PubMed Health web page. Scleroderma. Available at: Copyright © 2013.

Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol. Mar 2010a;22(2):133-138.

Agarwal SK. The genetics of systemic sclerosis. Discovery medicine. Aug 2010b;10(51):134-143.

Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The international journal of biochemistry & cell biology. Jan 2009;41(1):40-59.

Aggarwal BB, Prasad S, Reuter S, Kannappan R, Yadev VR, Park B, . . . Sung B. Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach. Current drug targets. Oct 2011;12(11):1595-1653.

Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in Systemic and Organ-Specific Autoimmune Diseases. Clinical reviews in allergy & immunology. Dec 14 2012.

Alexopoulos N, Vlachopoulos C, Aznaouridis K, Baou K, Vasiliadou C, Pietri P, . . . Stefanadis C. The acute effect of green tea consumption on endothelial function in healthy individuals. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. Jun 2008;15(3):300-305.

Arnson Y, Amital H, Agmon-Levin N, Alon D, Sanchez-Castanon M, Lopez-Hoyos M, . . . Shoenfeld Y. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmunity reviews. Jun 2011;10(8):490-494.

Au K, Singh MK, Bodukam V, Bae S, Maranian P, Ogawa R, . . . Khanna D. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis and rheumatism. Jul 2011;63(7):2078-2090.

Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y. High DNA oxidative damage in systemic sclerosis. The Journal of rheumatology. Dec 2010;37(12):2540-2547.

Ayres S, Jr., Mihan R. Is vitamin E involved in the autoimmune mechanism? Cutis; cutaneous medicine for the practitioner. Mar 1978;21(3):321-325.

Balbir-Gurman A, Braun-Moscovici Y. Scleroderma - new aspects in pathogenesis and treatment. Best practice & research. Clinical rheumatology. Feb 2012;26(1):13-24.

Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. Mar 2012;24(2):165-170.

Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. International journal of rheumatology. 2011;2011:721608.

Baron M, Hudson M, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. The Journal of rheumatology. Dec 2009;36(12):2737-2743.

Baumhakel M, Bohm M. Recent achievements in the management of Raynaud's phenomenon. Vascular health and risk management. 2010;6:207-214.

Belcaro G, Maquart FX, Scoccianti M, Dugall M, Hosoi M, Cesarone MR, . . . Feragalli B. TECA (Titrated Extract of Centella Asiatica): new microcirculatory, biomolecular, and vascular application in preventive and clinical medicine. A status paper. Panminerva medica. Sep 2011;53(3 Suppl 1):105-118.

Belch JJ, Shaw B, O'Dowd A, Saniabadi A, Leiberman P, Sturrock RD, Forbes CD. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thrombosis and haemostasis. Aug 30 1985;54(2):490-494.

Black MA, Green DJ, Cable NT. Exercise prevents age-related decline in nitric-oxide-mediated vasodilator function in cutaneous microvessels. The Journal of physiology. Jul 15 2008;586(14):3511-3524.

BMJ. Potassium para-aminobenzoate (Potaba) in scleroderma. Drug and therapeutics bulletin. Jun 7 1968;6(12):47-48.

Bonte F, Dumas M, Chaudagne C, Meybeck A. Influence of asiatic acid, madecassic acid, and asiaticoside on human collagen I synthesis. Planta medica. Apr 1994;60(2):133-135.

Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule. The American journal of clinical nutrition. Nov 2002;76(5):1151S-1157S.

Cai Y, Yu SS, Chen TT, Gao S, Geng B, Yu Y, . . . Liu PQ. EGCG inhibits CTGF expression via blocking NF-kappaB activation in cardiac fibroblast. Phytomedicine : international journal of phytotherapy and phytopharmacology. Jan 15 2013;20(2):106-113.

Carossino AM, Lombardi A, Matucci-Cerinic M, Pignone A, Cagnoni M. Effect of melatonin on normal and sclerodermic skin fibroblast proliferation. Clinical and experimental rheumatology. Sep-Oct 1996;14(5):493-498.

Castro SV, Jimenez SA. Biomarkers in systemic sclerosis. Biomarkers in medicine. Feb 2010;4(1):133-147.

Chang JZ, Yang WH, Deng YT, Chen HM, Kuo MY. EGCG blocks TGFbeta1-induced CCN2 by suppressing JNK and p38 in buccal fibroblasts. Clinical oral investigations. Mar 2013;17(2):455-461.

Chatterjee S. Systemic Scleroderma. Cleveland Clinic web page. Available at: August 1, 2010.

Clegg DO, Reading JC, Mayes MD, Seibold JR, Harris C, Wigley FM, . . . et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. The Journal of rheumatology. Jan 1994;21(1):105-110.

Clemens PJ, Furst DE. Systemic Sclerosis Lippincott Williams & Wilkins; 2003. NCT00114530. Available at: Accessed: 6/7/2013. NCT00501995. Available at: Accessed 6/7/2013.

Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Advances in experimental medicine and biology. 2007;595:197-212.

Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis research & therapy. 2012;14(3):R145.

de Souza RB, Macedo AR, Kuruma KA, Macedo PA, Borges CT. Pentoxyphylline in association with vitamin E reduces cutaneous fibrosis in systemic sclerosis. Clinical rheumatology. Oct 2009;28(10):1207-1212.

Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, . . . Webb DJ. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Journal of hypertension. Jan 2005;23(1):7-17.

Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmunity reviews. Jun 2003;2(4):181-191.

Dieude P, Boileau C, Allanore Y. Immunogenetics of systemic sclerosis. Autoimmunity reviews. Mar 2011;10(5):282-290.

Dooley A, Bruckdorfer KR, Abraham DJ. Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. Cardiology research and practice. 2012;2012:521958.

Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, . . . Bruckdorfer R. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Rheumatology. Nov 2010;49(11):2024-2036.

Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology. Jun 2012;51(6):1017-1026.

Elst EF, Van Suijlekom-Smit LW, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatric dermatology. Jan-Feb 1999;16(1):53-58.

Failli P, Palmieri L, D'Alfonso C, Giovannelli L, Generini S, Rosso AD, . . . Matucci-Cerinic M. Effect of N-acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis. Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society. Dec 2002;7(4):277-282.

Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. The Journal of rheumatology. Aug 1992;19(8):1207-1211.

Ferri FR. Ferri's Clinical Advisor 2013. Scleroderma. Available at:!/ContentPlayerCtrl/doPlayContent/3-s2.0-B9780323083737000285/{"scope":"all","query":"scleroderma ferri"}. Accessed: 6/7/2013.

Fiori G, Galluccio F, Braschi F, Amanzi L, Miniati I, Conforti ML, . . . Matucci-Cerinic M. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clinical and experimental rheumatology. May-Jun 2009;27(3 Suppl 54):51-54.

Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin. Arthritis and rheumatism. May 1977;20(4):975-984.

Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. The New England journal of medicine. May 7 2009;360(19):1989-2003.

Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. The open rheumatology journal. 2012;6:87-95.

Gabrielli A, Svegliati S, Moroncini G, Avvedimento EV. Pathogenic autoantibodies in systemic sclerosis. Current opinion in immunology. Dec 2007;19(6):640-645.

Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Seminars in immunopathology. Jul 2008;30(3):329-337.

Gaby AR. Natural remedies for scleroderma. Alternative medicine review : a journal of clinical therapeutic. Sep 2006;11(3):188-195.

Gayraud M. Raynaud's phenomenon. Joint, bone, spine : revue du rhumatisme. Jan 2007;74(1):e1-8.

Gohil KJ, Patel JA, Gajjar AK. Pharmacological Review on Centella asiatica: A Potential Herbal Cure-all. Indian journal of pharmaceutical sciences. Sep 2010;72(5):546-556.

Gomer RH. Circulating progenitor cells and scleroderma. Current rheumatology reports. Jul 2008;10(3):183-188.

Gordon JK, Spiera RF. Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Current opinion in rheumatology. Nov 2010;22(6):690-695.

Gougerot H, Hewitt J. [Scleroderma en plaques; combined action of p-aminobenzoic acid and alpha tocopherol]. Bulletin de la Societe francaise de dermatologie et de syphiligraphie. Jan-Feb 1951;58(1):42-43.

Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wiener medizinische Wochenschrift. 2008;158(1-2):19-28.

Gruson LM, Franks A, Jr. Scleredema and diabetic sclerodactyly. Dermatology online journal. 2005;11(4):3.

Guseva NG, Starovoitova MN, Mach ES. [Madecassol treatment of systemic and localized scleroderma]. Terapevticheskii arkhiv. 1998;70(5):58-61.

Hawk A and English III JC. Localized and Systemic Scleroderma. Seminars in Cutaneous Medicine and Surgery. 2001;20(1):27-37.

Heinberg LJ, Kudal I, White B, et al. Assessing Body Image in Patients with Systemic Sclerosis (Scleroderma): Validation of the Adapted Satisfaction With Appearance Scale. Body Image. 2007;4(1):79-86.

Heron E, Fornes P, Rance A, Emmerich J, Bayle O, Fiessinger JN. Brain involvement in scleroderma: two autopsy cases. Stroke; a journal of cerebral circulation. Mar 1998;29(3):719-721.

Herrick AL, Clark S. Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis. Annals of the rheumatic diseases. Feb 1998;57(2):70-78.

Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nature reviews. Rheumatology. Aug 2012;8(8):469-479.

Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American family physician. Oct 15 2008;78(8):961-968.

Hughes M, Herrick A. Systemic sclerosis. British journal of hospital medicine. Sep 2012;73(9):509-510, 511-506.

Hulshof MM, Pavel S, Breedveld FC, Dijkmans BA, Vermeer BJ. Oral calcitriol as a new therapeutic modality for generalized morphea. Archives of dermatology. Oct 1994;130(10):1290-1293.

Humbert P, Dupond JL, Agache P, Laurent R, Rochefort A, Drobacheff C, . . . Aubin F. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta dermato-venereologica. Dec 1993;73(6):449-451.

Hummers LK. Biomarkers of vascular disease in scleroderma. Rheumatology. 2008;47:21-22.

Ihler G, Chami-Stemmann H. 7-oxo-DHEA and Raynaud's phenomenon. Medical hypotheses. Mar 2003;60(3):391-397.

Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. Journal of clinical immunology. Jan 2007;27(1):19-35.

Jimenez SA, Diamond HS. Medscape reference. Scleroderma. Available at: Accessed 6/3/2013. 2012.

Jimenez SA. and Diamond HS. 2012. Medscape reference. Scleroderma. Available at: Accessed 6/3/2013. [Online].

Jungel A, Distler JH, Gay S, Distler O. Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? Expert review of clinical immunology. Jul 2011;7(4):475-480.

Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative medicine review : a journal of clinical therapeutic. Jun 2009;14(2):141-153.

Khoo JJ, Pratt EJ. Phaeochromocytoma mimicking scleroderma. International journal of endocrinology. 2011;2011:917453.

Klein-Weigel P, Opitz C, Riemekasten G. Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. VASA. Zeitschrift fur Gefasskrankheiten. Jan 2011;40(1):6-19.

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, . . . Matucci-Cerinic M. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Annals of the rheumatic diseases. May 2009;68(5):620-628.

Krause L, Becker MO, Brueckner CS, Bellinghausen CJ, Becker C, Schneider U, . . . Riemekasten G. Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Annals of the rheumatic diseases. Nov 2010;69(11):1951-1957.

Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Annals of the rheumatic diseases. Jun 2011;70(6):1104-1107.

Leask A. Egr-ly awaiting a "personalized medicine" approach to treat scleroderma. Journal of cell communication and signaling. Jun 2012;6(2):111-113.

Malenfant D, Summers K, Seney S, et al. Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When Raynaud’s phenomenon Improves. ISRN Rheumatol. 2011;2011:580704.

Man A, Zhu Y, Zhang Y, Dubreuil M, Rho YH, Peloquin C, . . . Choi HK. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Annals of the rheumatic diseases. Jul 2013;72(7):1188-1193.

Maquart FX, Chastang F, Simeon A, Birembaut P, Gillery P, Wegrowski Y. Triterpenes from Centella asiatica stimulate extracellular matrix accumulation in rat experimental wounds. European journal of dermatology : EJD. Jun 1999;9(4):289-296.

Maricq HR, Weinrich MC, Valter I, Palesch YY, Maricq JG. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders. The Journal of rheumatology. Dec 1996;23(12):2068-2078.

Martínez JD. Raynaud phenomenon - First Consult. 2011;!/ContentPlayerCtrl/doPlayContent/21-s2.0-1014243/{"scope":"all","query":"raynaud"}. Accessed 3/26/2013.

Mayes MD. The genetics of scleroderma: looking into the postgenomic era. Current opinion in rheumatology. Nov 2012;24(6):677-684.

Mayo Clinic. Raynaud's Disease: Treatments and Drugs. 2011; Accessed December 21, 2012.

Mayo Clinic. Scleroderma. Treatments and Drugs. Available at: Last updataed 10/16/2010. Accessed: 6/5/2013.

Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. The Journal of rheumatology. Jun 2012;39(6):1241-1247.

Meyers D. Treatment of scleroderma. The Medical journal of Australia. Jun 11 1977;1(24):887.

Mok MY, Lau CS, Chiu SS, Tso AW, Lo Y, Law LS, . . . Lam KS. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis and rheumatism. May 2011;63(5):1387-1395.

Mora GF. Systemic sclerosis: environmental factors. The Journal of rheumatology. Nov 2009;36(11):2383-2396.

Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis care & research. Sep 2012;64(9):1405-1414.

Nashel J, Steen V. Scleroderma mimics. Current rheumatology reports. Feb 2012;14(1):39-46.

NCBI 2011. Raynaud's Phenomenon. Available at: Last reviewed June 2011.

NIAMS. Scleroderma. 2012.

NIAMS. What Is Scleroderma? Fast Facts: An Easy-to-Read Series of Publications for the Public. Website: Accessed 01/12/2013. 2010.

Opitz C, Klein-Weigel PF, Riemekasten G. Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. VASA. Zeitschrift fur Gefasskrankheiten. Jan 2011;40(1):20-30.

O'Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. Sep 2012;51(9):1540-1549.

Oriente P, Scarpa R, Biondi C, Riccio A, Farinaro C, Del Puente A. Progressive systemic sclerosis and S-adenosylmethionine. Clinical rheumatology. Sep 1985;4(3):360-361.

Ostojic P, Damjanov N. Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis. Rheumatology international. Aug 2011;31(8):1051-1054.

Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? The FEBS journal. Jul 2006;273(13):2813-2838.

Panichi V, Migliori M, Taccola D, Consani C, Giovannini L. Effects of calcitriol on the immune system: new possibilities in the treatment of glomerulonephritis. Clinical and experimental pharmacology & physiology. Nov 2003;30(11):807-811.

Paocharoen V. The efficacy and side effects of oral Centella asiatica extract for wound healing promotion in diabetic wound patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Dec 2010;93 Suppl 7:S166-170.

Park G, Yoon BS, Moon JH, Kim B, Jun EK, Oh S, . . . You S. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. The Journal of investigative dermatology. Oct 2008;128(10):2429-2441.

Patel JC. Functions of endothelium. Indian Journal of Medical Sciences. 2001;55(3):165-166.

Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. The Journal of rheumatology. Jan 1997;24(1):73-80.

Pinto AL, Oliveira NC, Gualano B, Christmann RB, Painelli VS, Artioli GG, . . . Lima FR. Efficacy and safety of concurrent training in systemic sclerosis. Journal of strength and conditioning research / National Strength & Conditioning Association. May 2011;25(5):1423-1428.

Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, . . . Taieb A. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. The British journal of dermatology. Nov 2012;167(5):1138-1144.

Priestley GC, Brown JC. Effects of potassium para-aminobenzoate on growth and macromolecule synthesis in fibroblasts cultured from normal and sclerodermatous human skin, and rheumatoid synovial cells. The Journal of investigative dermatology. Apr 1979;72(4):161-164.

Punithavathi D, Venkatesan N, Babu M. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. British journal of pharmacology. Aug 2003;139(7):1342-1350.

Rodella LF, Favero G, Foglio E, Rossini C, Castrezzati S, Lonati C, Rezzani R. Vascular endothelial cells and dysfunctions: role of melatonin. Front Biosci (Elite Ed). 2013;5:119-129.

Rosato E, Borghese F, Pisarri S, Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clinical rheumatology. Dec 2009c;28(12):1379-1384.

Rosato E, Cianci R, Barbano B, Menghi G, Gigante A, Rossi C, . . . Salsano F. N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis. Acta pharmacologica Sinica. Sep 2009b;30(9):1283-1288.

Rosato E, Zardi EM, Barbano B, Menghi G, Cianci R, Amoroso A, . . . Salsano F. N-acetylcysteine infusion improves hepatic perfusion in the early stages of systemic sclerosis. International journal of immunopathology and pharmacology. Jul-Sep 2009a;22(3):763-772.

Salsano F, Letizia C, Proietti M, Rossi C, Proietti AR, Rosato E, Pisarri S. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon. International journal of immunopathology and pharmacology. Oct-Dec 2005;18(4):761-770.

Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, Gabrielli A. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. The Journal of rheumatology. Oct 2001;28(10):2257-2262.

Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. Feb 2004;43(2):192-197.

Semenova NI. [The role of therapeutic exercise in the overall therapy of scleroderma and psoriatic arthritis]. Vestnik dermatologii i venerologii. Apr 1973;47(4):60-64.

Sfrent-Cornateanu R, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E. Antioxidant defense capacity in scleroderma patients. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2008;46(6):836-841.

Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. Sep 2005;41(13):1955-1968.

Shenouda SM, Vita JA. Effects of flavonoid-containing beverages and EGCG on endothelial function. Journal of the American College of Nutrition. Aug 2007;26(4):366S-372S.

Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. Nov 30 2000;155(1-3):1-15.

Slominski A, Janjetovic Z, Tuckey RC, Nguyen MN, Bhattacharya KG, Wang J, . . . Postlethwaite AE. 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. The Journal of clinical endocrinology and metabolism. Feb 2013;98(2):E298-303.

Smith MR, Gangireddy SR, Narala VR, Hogaboam CM, Standiford TJ, Christensen PJ, . . . Reddy RC. Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury. American journal of physiology. Lung cellular and molecular physiology. May 2010;298(5):L616-625.

Song K, Peng S, Sun Z, Li H, Yang R. Curcumin suppresses TGF-beta signaling by inhibition of TGIF degradation in scleroderma fibroblasts. Biochemical and biophysical research communications. Aug 12 2011;411(4):821-825.

Strong AM, Campbell A, Thomson J. The effect of oral linoleic acid and gamma-linolenic acid (Efamol [G]). The British journal of clinical practice. Nov-Dec 1985;39(11-12):444-445.

Takehara K and Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology. 2005;44:274-279.

Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. Sep 2012;142(3):614-621.

Tinken TM, Thijssen DH, Black MA, Cable NT, Green DJ. Time course of change in vasodilator function and capacity in response to exercise training in humans. The Journal of physiology. Oct 15 2008;586(Pt 20):5003-5012.

Tjonna AE, Rognmo O, Bye A, Stolen TO, Wisloff U. Time course of endothelial adaptation after acute and chronic exercise in patients with metabolic syndrome. Journal of strength and conditioning research / National Strength & Conditioning Association. Sep 2011;25(9):2552-2558.

Todisco M. Effectiveness of a treatment based on melatonin in five patients with systemic sclerosis. American journal of therapeutics. Jan-Feb 2006;13(1):84-87.

Tourkina E, Gooz P, Oates JC, Ludwicka-Bradley A, Silver RM, Hoffman S. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. American journal of respiratory cell and molecular biology. Jul 2004;31(1):28-35.

Tsai CF, Hsu YW, Ting HC, Huang CF, Yen CC. The in vivo antioxidant and antifibrotic properties of green tea (Camellia sinensis, Theaceae). Food chemistry. Feb 15 2013;136(3-4):1337-1344.

Vacca A, Cormier C, Mathieu A, Kahan A, Allanore Y. Vitamin D levels and potential impact in systemic sclerosis. Clinical and experimental rheumatology. Nov-Dec 2011;29(6):1024-1031.

Varga J. Systemic sclerosis: an update. Bulletin of the NYU hospital for joint diseases. 2008;66(3):198-202.

Widgerow AD, Chait LA, Stals R, Stals PJ. New innovations in scar management. Aesthetic plastic surgery. May-Jun 2000;24(3):227-234.

Widlansky ME, Hamburg NM, Anter E, Holbrook M, Kahn DF, Elliott JG, . . . Vita JA. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. Journal of the American College of Nutrition. Apr 2007;26(2):95-102.

Wu D, Wang J. The ability of green tea to alleviate autoimmune diseases: fact or fiction? Expert review of clinical immunology. Nov 2011;7(6):711-713.

Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, . . . Tipoe GL. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr. Mar 21 2013.

Zarafonetis CJ, Dabich L, Devol EB, Skovronski JJ, Negri D, Yuan WY. Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. Respiration; international review of thoracic diseases. 1989;56(1-2):22-33.

Zarafonetis CJ, Dabich L, Negri D, Skovronski JJ, DeVol EB, Wolfe R. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. Journal of clinical epidemiology. 1988a;41(2):193-205.

Zarafonetis CJ, Dabich L, Skovronski JJ, DeVol EB, Negri D, Yuan W, Wolfe R. Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. Clinical and experimental rheumatology. Jul-Sep 1988b;6(3):261-268.

Zarafonetis CJ. Para-aminobenzoic acid therapy in scleroderma and lymphoblastoma cutis. The Journal of laboratory and clinical medicine. Nov 1948;33(11):1462.

Zhou H, Beevers CS, Huang S. The targets of curcumin. Current drug targets. Mar 1 2011;12(3):332-347.